Landscapes / Companies
Eisai Korea Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
1
in active trials · 2 in all
Trials
1 active
8 since 2021
Drugs1
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
JAK inhibitor |
Eisai |
Approved in Japan | 30 Nov 2027Phase 4 trial completes | ||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 30 Nov 2027 · Phase 4 trial completes | ||||
| Also tested for | Ulcerative Colitis | ||||
| Open drug page | |||||
About
- No active trial
- Donepezil
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021